{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-017922","form_type":"8-K","ticker":"OM","cik":"0001484612","company_name":"Outset Medical, Inc.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.301878+00:00","generated_at":"2026-06-05T21:58:59.683882+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Outset Medical Q4 revenue $30.5M, FY revenue $130.4M; CCO Steve Williamson departs March 1","bullets":["FY 2023 revenue $130.4M (+13% YoY); Q4 revenue $30.5M (-4.7% YoY) due to product revenue decline.","Q4 gross margin 25.3% (non-GAAP 26.7%), up ~900 bps YoY; FY gross margin 22.2% (non-GAAP 23.6%).","Tablo installed base 5,350 consoles exiting 2023; recurring revenue exceeded 50% of total revenue.","2024 guidance reaffirmed: revenue $145-153M (+12-18% YoY); non-GAAP gross margin low-30% range.","CCO Steve Williamson to depart March 1, 2024 to become CEO of another public med device company; no dispute."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-017922","json":"https://secwatch.observer/filing/0000950170-24-017922.json","markdown":"https://secwatch.observer/filing/0000950170-24-017922.md","text":"https://secwatch.observer/filing/0000950170-24-017922.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/0000950170-24-017922-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/om-20240216.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:58:59.683882+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d85e027f19fe85ba31d7f4b3eb604421df997676","claim":"Outset Medical, Inc. updated its fourth quarter and full year ended December 31, 2023 guidance (reaffirmed).","evidence_excerpt":"On February 21, 2024, Outset Medical, Inc. (the “Company”) issued a press release and will hold its fourth quarter and full year 2023 earnings conference call announcing the Company’s financial results for the quarter and year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/0000950170-24-017922-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6376a97021","claim":"Steve Williamson departed as Chief Commercial Officer at Outset Medical, Inc..","evidence_excerpt":"On February 16, 2024, Steve Williamson informed the Company of his decision to depart from the Company and his role as Chief Commercial Officer, effective March 1, 2024, to become the CEO of another publicly traded medical device company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484612/000095017024017922/0000950170-24-017922-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"depart"},{"label":"Role","value":"Chief Commercial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}